SaMD & Connected Device Premarket Strategy: 2025-2026 Guide

# SaMD & Connected Device Premarket Strategy: 2025-2026 Guide For medical device sponsors planning a premarket submission in the 2025-2026 timeframe, particularly for Software as a Medical Device (SaMD) and connected devices, building a forward-looking regulatory strategy is essential. The landscape for digital health technology is dynamic, with regulatory expectations—especially concerning cybersecurity—evolving rapidly. A proactive approach that integrates these requirements into the entire product lifecycle is no longer optional; it is a prerequisite for a smooth and successful regulatory review. Beyond establishing the basic device classification and selecting a probable regulatory pathway like a 510(k) or De Novo, a robust strategy must anticipate and address areas of heightened FDA scrutiny. For a modern connected device, this means treating cybersecurity not as a final checklist item but as a core component of design, development, and postmarket management. By embedding best practices for documentation, such as creating a Software Bill of Materials (SBOM) and conducting thorough threat modeling from the outset, sponsors can significantly de-risk their submission and reduce review timelines. Leveraging the FDA's Q-Submission program strategically provides a critical mechanism to gain clarity on expectations for novel technologies, ensuring the final submission package is built on a foundation of regulatory alignment. ## Key Points * **Cybersecurity is a Lifecycle Commitment:** FDA expects sponsors to implement a Secure Product Development Framework (SPDF), integrating cybersecurity considerations into every phase of the device lifecycle, from initial design inputs to postmarket vulnerability management. * **Proactive Documentation is Non-Negotiable:** A comprehensive Software Bill of Materials (SBOM) is now a standard expectation. This, along with detailed threat modeling and a robust cybersecurity management plan, must be developed early and maintained throughout the product's life. * **Integrate Security into Design Controls:** Under 21 CFR regulations governing Quality Management Systems, cybersecurity requirements must be treated as formal design inputs, with corresponding verification and validation activities to prove their effectiveness. * **Leverage Q-Submissions to Reduce Uncertainty:** For devices with novel features, AI/ML algorithms, or complex connectivity, the Q-Submission program is an invaluable tool for clarifying FDA's testing and data expectations long before the final marketing submission. * **Plan for Postmarket Evolution:** A successful premarket strategy includes a clear plan for postmarket surveillance and management, particularly for AI/ML algorithm updates and emerging cybersecurity threats. * **Traceability is Paramount:** Sponsors must be able to demonstrate clear traceability from security risks and requirements through design mitigations to the verification and validation testing that proves those mitigations are effective. ## Integrating Cybersecurity into the Total Product Lifecycle Historically, some device manufacturers may have viewed cybersecurity as a final-stage testing activity. Today, FDA's guidance, such as **Cybersecurity in Medical Devices: Quality System Considerations and Content of Premarket Submissions**, makes it clear that this approach is insufficient. The agency expects a proactive, lifecycle-based approach, often referred to as a Secure Product Development Framework (SPDF). ### The Secure Product Development Framework (SPDF) An SPDF is a set of processes that reduce the number and severity of vulnerabilities in products throughout their lifecycle. It is not a single document but a commitment integrated into the Quality Management System (QMS). Key elements include: 1. **Security Risk Management:** This process runs parallel to the safety risk management activities outlined in ISO 14971. It involves identifying security risks, analyzing their potential impact on device safety and effectiveness, and implementing controls to mitigate them to an acceptable level. 2. **Threat Modeling:** This is a systematic process for identifying potential threats to a device and its ecosystem. By analyzing the device's architecture, data flows, and interfaces, sponsors can anticipate how an attacker might compromise the system. This proactive analysis informs the device's security architecture and testing strategy. 3. **Security Architecture:** Sponsors must design and document a comprehensive security architecture that addresses identified threats. This includes controls for authentication, authorization, cryptography, code integrity, and secure communications. 4. **Third-Party Software Component Management:** Nearly all modern SaMD relies on third-party software components. The SPDF must include rigorous processes for managing these components, including maintaining an accurate SBOM and having a plan to monitor and manage vulnerabilities discovered in them. ### Aligning Design Controls with Cybersecurity Under 21 CFR Part 820, the Quality System Regulation, medical device design must follow a structured process known as design controls. Cybersecurity must be fully integrated into this process: * **Design Inputs:** Security requirements (e.g., "All patient data must be encrypted in transit using TLS 1.2 or higher," "User authentication must be required to change therapy settings") must be formally documented as design inputs. These are derived from the threat model and security risk analysis. * **Design Outputs:** The design outputs are the specifications that meet the input requirements. This includes the security architecture, cryptographic specifications, and secure coding standards. * **Design Verification:** This is the process of confirming that the design outputs meet the design inputs. Activities include code reviews, static/dynamic code analysis, and testing of individual security controls. * **Design Validation:** This confirms that the finished device meets user needs and intended uses in its intended environment. For cybersecurity, this often involves penetration testing and vulnerability scanning on the final, production-equivalent device to ensure it is resilient to attack. ## Essential Documentation for a Modern SaMD Submission A premarket submission for a connected device must contain compelling evidence of its cybersecurity posture. This evidence is presented through clear, comprehensive documentation. ### The Software Bill of Materials (SBOM) An SBOM is a formal, machine-readable inventory of the software components and dependencies used in a device. Its purpose is to provide transparency into the device's software supply chain. For the FDA and the sponsor, the SBOM is critical for: * **Vulnerability Management:** When a new vulnerability is discovered in a common open-source library (e.g., Log4j), an accurate SBOM allows the manufacturer to quickly determine if their devices are affected. * **Risk Assessment:** It allows reviewers to understand the potential attack surface introduced by third-party components. * **Lifecycle Management:** It provides a baseline for managing software updates and patches. ### Comprehensive Threat Modeling and Risk Assessment The submission should include a detailed report of the threat modeling activities performed. This documentation should describe the methodology used (e.g., STRIDE), the system architecture analyzed, and the threats identified. For each threat, the security risk assessment should document: * The potential vulnerability and attack vector. * The potential impact on the device's safety and essential performance. * The mitigation or control implemented to address the risk. * A reference to the verification and validation testing that proves the control is effective. ## Scenario: A Class II AI-Enabled Diagnostic SaMD To illustrate these concepts, consider a hypothetical device planned for submission in 2025. ### Scenario Description A cloud-based SaMD that uses an AI/ML algorithm to analyze MRI scans to help radiologists identify potential signs of early-stage disease. The software receives images from a hospital's Picture Archiving and Communication System (PACS), processes them in the cloud, and sends a report back to the hospital's Electronic Health Record (EHR) system. #### What FDA Will Scrutinize * **Cybersecurity and Data Integrity:** How is patient data protected during upload, processing, and storage? How does the system authenticate and authorize users (radiologists, administrators)? How is the device protected from malware that may exist on the hospital network? Crucially, how is the integrity of the AI/ML algorithm itself protected from tampering? * **AI/ML Algorithm Validation:** How was the algorithm trained, tuned, and validated? What were the key performance metrics? Is the dataset representative of the intended patient population? What is the plan for managing algorithm changes and avoiding model drift after deployment (i.e., a Predetermined Change Control Plan)? * **Interoperability and Connectivity:** How does the SaMD ensure a secure and reliable connection to hospital PACS and EHR systems? What happens in the event of a network failure? #### Critical Documentation and Data to Provide * **A Complete Cybersecurity File:** This includes the threat model, security risk assessment, penetration testing report, and a detailed cybersecurity management plan for postmarket monitoring. * **A Complete SBOM:** This must cover all components of the cloud platform and any on-premise software. * **An AI/ML Transparency File:** Detailed documentation on the algorithm's design, training and testing datasets, performance validation, and a comprehensive Predetermined Change Control Plan outlining the specific modifications the sponsor intends to make and the validation method for each. ## Strategic Considerations and the Role of Q-Submission For a device as complex as the one in the scenario, relying solely on a predicate-based 510(k) without prior FDA engagement is a high-risk strategy. The FDA's Q-Submission program is the primary mechanism for sponsors to obtain feedback from the agency on their regulatory approach prior to a marketing submission. A sponsor of this AI-enabled SaMD should strategically use a Q-Submission to ask specific questions, such as: * "Does the agency concur that our proposed penetration testing plan provides sufficient evidence of the device's security posture?" * "Is the validation methodology for our AI/ML algorithm, as described in our proposed testing protocol, adequate to support a determination of substantial equivalence?" * "Does the agency agree with our proposed framework for a Predetermined Change Control Plan for future algorithm modifications?" Gaining alignment on these key issues months before the final 510(k) or De Novo submission can prevent significant delays, such as major Additional Information (AI) requests, and increases the probability of a successful and timely review. ## Finding and Comparing REACH Only Representative Providers While navigating FDA regulations is a primary focus for many device sponsors, those marketing devices globally must also address requirements in other key markets, such as the European Union. For devices that incorporate chemical substances, this can include compliance with the EU's Registration, Evaluation, Authorisation and Restriction of Chemicals (REACH) regulation. A REACH Only Representative (OR) is a natural or legal person established physically in the European Economic Area (EEA) appointed by a non-EEA manufacturer to fulfill the registration obligations of the importers. Choosing the right partner is crucial for ensuring compliance. When evaluating providers, sponsors should consider their experience with medical devices, their understanding of the specific substances involved, and the scope of services they offer, from registration to ongoing compliance management. To find qualified vetted providers [click here](https://cruxi.ai/regulatory-directories/reach_only_rep) and request quotes for free. ## Key FDA references * Cybersecurity in Medical Devices: Quality System Considerations and Content of Premarket Submissions * FDA's Q-Submission Program guidance * 21 CFR Part 807, Subpart E – Premarket Notification Procedures * General FDA guidance on AI/ML-enabled medical devices This article is for general educational purposes only and is not legal, medical, or regulatory advice. For device-specific questions, sponsors should consult qualified experts and consider engaging FDA via the Q-Submission program. --- *This answer was AI-assisted and reviewed for accuracy by Lo H. Khamis.*